Change in macular thickness in a case of refractory diabetic macular edema with dexamethasone intravitreal implant in comparison to intravitreal bevacizumab: A case report.
Indian J Ophthalmol
;
2012 May; 60(3): 234-235
Article
in English
| IMSEAR
| ID: sea-139482
ABSTRACT
We report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained-release intravitreal implant (Ozurdex®; Allergan, Inc, Irvine, CA, USA). Patient presented to us with persistent clinically significant macular edema (CSME) in both eyes. Right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 mL (Avastin®; Genentech Inc., South San Francisco, CA, USA) with an interval of four weeks. After six weeks of follow-up, dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema (ME) was found even after second intravitreal bevacizumab injection in the left eye.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Male
/
Dexamethasone
/
Visual Acuity
/
Macular Edema
/
Follow-Up Studies
/
Disease Progression
/
Adult
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
Type of study:
Observational study
/
Prognostic study
Language:
English
Journal:
Indian J Ophthalmol
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS